Skip to main content
SpringerLink
Log in

Effects of interferon γ on the proliferation and modulation of cell-surface structures of human ovarian carcinoma cell lines

  • Original Papers
  • Experimental Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Platinum-containing regimens are very effective in the primary treatment of ovarian cancer. However, upon subsequent treatment most tumors develop multidrug resistance. The clinical application of biological response modifiers like interferon γ (IFNγ) in advanced ovarian cancer is therefore of increasing interest. Permanent ovarian cancer cell lines are suitable for investigating the mode of action and the potential clinical effectiveness of such response modifiers. IFNγ is known to modulate many cellular functions. In this study it was compared for its antiproliferative and antigen-modulatory activity on the expression of tumor-associated (CA-125, HMFG, CEA) and major histocompatibility complex (MHC) class I and II antigens as well as of the epidermal growth factor (EGF) receptor on 20 newly established human ovarian carcinoma cell lines. IFNγ in concentrations of 10, 50 and 100 U/ml was used to study its antigen-modulatory effect, and at additional 1 U/ml and 1000 U/ml to assess its antiproliferative effect on the cells. The cells were incubated with IFN for 4 days. Two cell lines showed strong antiproliferative activity even at minimal doses (up to 50 U/ml). Intermediate growth inhibition between 34% and 84% was observed in 15 cell lines with higher doses. Three lines were resistant to IFNγ. Independent of the antiproliferative effect, IFNγ enhanced the expression of MHC class I and MHC class II in nearly all cell lines. Upregulation was also observed for most of the tumor-associated antigens (TAA) and EGF receptor expression. A downregulation was noticed but rarely. The fact that IFNγ showed an antiproliferative activity on the majority of the cell lines is of clinical relevance. The in vitro modulation of cell-surface determinants by IFNγ warrants special attention. The enhanced expression of TAA and MHC antigens can improve immunogenicity of the tumor cells and may explain the therapeutic effects observed under IFN therapy in ovarian cancer. By contrast, enhanced expression of the EGF receptor, often associated with poor patient survival rates, may be an undesirable side-effect of IFN therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

CA-125:

tumor-associated antigen CA-125

CEA:

carcinoembryonic antigen

EGF:

epidermal growth factor

FACS:

fluorescence-activated cell sorter

FCS:

tetal calf serum

HMFG:

human milk fat globule antigen

IFN:

interferon

MHC:

major histocompatibility complex

PBS:

phosphate-buffered saline

TAA:

tumor-associated antigen

References

  • Abdulhay G, Disaia PJ, Blessing JA, Creasman WT (1985) Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies: Gynecologic Oncology Group Study. Am J Obstet Gynecol 152:418–423

    Google Scholar 

  • D'Acquisto R, Markman M, Hakes T, Rubin S, Hoskins W, Lewis JR (1988) A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma. J Clin Oncol 6:689–695

    Google Scholar 

  • Basham TY, Merigan TC (1983) Recombinant interferon-gamma increases HLA-DR synthesis and expression. J Immunol 130:1492–1494

    Google Scholar 

  • Bast RC, Klug TL, St. John E, Jenison E, Niloof JM, Lazarus H, Berkowitz RS, Leavitt T, Parker L, Zurawski VR, Knapp RC (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883–887

    Google Scholar 

  • Berchuck A, Rodriguez GC, Kamel A, Dodge RK, Soper JT, Clarke-Pearson DL, Bast Jr RC (1991) Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol 164:669–674

    Google Scholar 

  • Berek JS, Hacker NF, Lichtenstein A, Jung T, Spina C, Knox RM, Brady, J, Greene T, Ettinger LM, Lagasse LD, Bonnem EM, Spiegel RJ (1985) Intraperitoneal recombinant alpha interferon for “salvage” immunotherapy in stage III epithelial ovarian cancer: a gynecologic oncology group study. Cancer Res 45:4447–4453

    Google Scholar 

  • Berek JS, Welander C, Schink JC, Grossberg H, Mantz FJ, Zigelboim J (1991) Phase I–II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer. Gynecol Oncol 40:237–243

    Google Scholar 

  • Borden EC, Groveman DS, Nasu T, Reznikoff C, Bryan GT (1984) Antiproliferative activities of interferons against human bladder carcinoma cell lines invitro. J Urol 132:800–803

    Google Scholar 

  • Carrel S, Schmidt-Kessen A, Giuffre L (1985) Recombinant interferongamma can induce the expression of HLA-DR and-DC on DR-negative melanoma cells and enhance the expression of HLA-ABC and tumor-associated antigens. Eur J Immunol 15:118–123

    Google Scholar 

  • Dhokia B, Canney PA, Pectasides D, Munro AJ, Moore M, Wilkinson PM, Self C, Epenetos AA (1986) A new immunoassay using monoclonal antibodies HMFG1 and HMFG2 together with an existing marker CA 125 for the serological detection and management of epithelial ovarian cancer. Br J Cancer 54:891–895

    Google Scholar 

  • Epenetos AA, Mather S, Granowska M, Nimmon CC, Hawkins CR, Britton KE, Shepherd J, Taylor-Papadimetriou J, Durbin H, Macpas JS, Bodmer WF (1982) Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast and gastrointestinal tumours. Lancet II:999–1004

    Google Scholar 

  • Garbe C, Krasagakis K, Zouboulis CC, Schroeder K, Krüger S, Stadler R, Orfanos CE (1990) Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype. J Invest Dermatol 95:231–237

    Google Scholar 

  • Gastl G, Marth C, Leiter E, Gattringer C, Mayer I, Daxenbichler G, Flener R, Huber Ch (1985) Effects of human recombinant interferon-alpha-2-arg and-gamma on human breast cancer cell lines: dissociation of antiproliferative activity and induction of HLA-DR antigen expression. Cancer Res 45:2957–2961

    Google Scholar 

  • Greiner JW, Hand PH, Noguchi P, Fisher PB, Pestka S, Schlom J (1984) Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte α-interferon treatment. Cancer Res 44:3208–3214

    Google Scholar 

  • Greiner JW, Fisher PB, Pestka S, Schlom J (1986) Differential effects of recombinant human leukocyte interferons on cell surface antigen expression. Cancer Res 46:4984–4990

    Google Scholar 

  • Greiner JW, Guadagni F, Noguchi P, Pestka S, Colcher D, Fisher PB, Schlom J (1989) Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. Science 235:895–898

    Google Scholar 

  • Imai K, Ng AK, Glassy MC, Ferrone S (1981) Differential effect of interferon on the expression of tumor-associated antigens and histocompatibility antigens on human melanoma cells: relationship to susceptibility to immune lysis mediated by monoclonal antibodies. J Immunol 127:505–508

    Google Scholar 

  • Kübler JP, Oberley TD, Meisner LF, Sidky YA, Reznikoff CA, Borden EC, Cummings KB, Bryan GT (1987) Effect of interferon alpha interferon beta and interferon gamma on the in vitro growth of human renal adenocarcinoma cells. Invest New Drugs 5:21–29

    Google Scholar 

  • Kurzrock R, Rosenblum MG, Sherwin SA (1985) Pharmacokinetics, single-dose tolerance and biological activity of recombinant gamma-interferon in cancer patients. Cancer Res 45:2866–2877

    Google Scholar 

  • Malissen B, Rebai N, Liabeuf A, Mawas C (1982) Human cytotoxic cell structures associated with expression of cytolysis. I. Analysis at the clonal cell level of the cytolysis-inhibiting effect of 7 monoclonal antibodies. Eur J Immunol 12:739–747

    Google Scholar 

  • Marth C, Zech J, Böck G, Mayer I, Daxenbichler G (1987) Effects of retinoids and interferon-gamma on cultured breast cancer cells in comparison with tumor necrosis factor alpha. Int J Cancer 40:840–845

    Google Scholar 

  • Marth C, Fuith LC, Böck G, Daxenbichler G, Dapunt O (1989a) Modulation of ovarian carcinoma tumor marker CA-125 by gamma-interferon. Cancer Res 49:6538–6542

    Google Scholar 

  • Marth C, Helmberg M, Mayer I, Fuith LC, Daxenbichler C, Dapunt O (1980b) Effects of biological response modifiers on ovarian carcinoma cell lines. Anticancer Res 9:461–468

    Google Scholar 

  • Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J (1984) Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44:1002–1007

    Google Scholar 

  • Möbus V, Kreienberg R (1986) Der Wert des Tumormarkers CA-125 beim Ovarialkarzinom im Vergleich mit anderen Markern. In: Wüst G (ed) Tumormarker. Steinkopff, Darmstadt

    Google Scholar 

  • Möbus V, Gerharz CD, Press U, Moll R, Beck T, Mellin W, Pollow K Knapstein PG, Kreienberg R (1992) Morphological, immunohistochemical and biochemical characterization of six newly established human ovarian carcinoma cell lines. Int J Cancer 52:76–84

    Google Scholar 

  • Mutch DG, Massad S, Kao MS, Collins JL (1986) Proliferative and antiproliferative effects of interferon-gamma and tumor necrosis factoralpha on cell lines derived from cervical and ovarian malignancies. Am J Obstet Gynecol 163:1920–1924

    Google Scholar 

  • Nickoloff BJ, Basham TY, Merigan TC, Morhenn VB (1985) Immunomodulatory and antiproliferative effect of recombinant alpha, beta, gamma interferons on cultured human malignant squamous cell lines, SCL-1 and SW-1271. J Invest Dermatol 84:487–490

    Google Scholar 

  • Pateisky N, Philipp K, Skodler WD, Czerwenka K, Hamilton G, Burchell J (1985) Radioimmunodetection in patients with suspected ovarian cancer. J Nucl Med 26:1369–1376

    Google Scholar 

  • Petru E, Seven BO, Perras J, Boike G, Ramos R, Nguyen H, Averette HE (1990) Comparative chemosensitivity profiles in four human ovarian carcinoma cell lines measuring ATP bioluminescence. Gynecol Oncol 38:155–160

    Google Scholar 

  • Rebai N, Malissen B, Pierres M, Accola RS, Corte G, Mawas C (1983) Distinct HLA-DR epitopes and distinct families of HLA-DR molecules defined by 15 monoclonal antibodies (mAb) either anti-DR or allo-anti-Iak crossreacting with human DR molecule. I. Cross-inhibition studies of mAb cell surface fixation and differential binding of mAb to detergent-solubilized HLA molecules immobilized to a solid phase by a first mAb. Eur J Immunol 13:106–111

    Google Scholar 

  • Rodriguez GC, Berchuck A, Whitaker RS, Schlossman D, Clarke-Pearson DL, Bast RC Jr (1991) Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor. Am J Obstet Gynecol 164:745–750

    Google Scholar 

  • Scambia G, Panici PB, Battaglia F, Ferrandina G, Gaggini C, Manusco S (1991) Presence of epidermal growth factor (EGF) receptor and proliferative response to EGF in six human ovarian carcinoma cell lines. Int J Gynecol Cancer 1:253–258

    Google Scholar 

  • Thoya T, Iwamasa T, Maeyama M (1986) Biochemical and immunohistochemical studies on carcinoembryonic antigen of ovarian mucinous and serous tumours. Gynecol Oncol 23:291–293

    Google Scholar 

  • Ücer U, Bartsch H, Scheurich P, Pfizenmaier K (1985) Biological effects of gamma-interferon on human tumor cells: quantity and affinity of cell membrane receptors for gamma-interferon in relation to growth inhibition and induction of HLA-DR expression. Int J Cancer 36:103–108

    Google Scholar 

  • Welander CE (1987) Use of interferon in the treatment of ovarian cancer as a single agent and in combination with cytotoxi drugs. Cancer 59:617–619

    Google Scholar 

  • Willson JKV, Bittner G, Borden EC (1984) Antiproliferative activity of human interferons against ovarian cancer cells grown in human tumor stem cell assay. J Interferon Res 4:441–447

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, University of Ulm, Prittwitzstrasse 43, W-7900, Ulm, Germany

    V. J. Möbus, W. Asphal & R. Kreienberg

  2. Department of Obstetrics and Gynecology, University of Mainz, Langenbeckstrasse 1, W-6500, Mainz, Germany

    P. G. Knapstein

Authors
  1. V. J. Möbus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Asphal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. G. Knapstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Kreienberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Möbus, V.J., Asphal, W., Knapstein, P.G. et al. Effects of interferon γ on the proliferation and modulation of cell-surface structures of human ovarian carcinoma cell lines. J Cancer Res Clin Oncol 120, 27–34 (1993). https://doi.org/10.1007/BF01200721

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01200721

Key words

Search

Navigation